SCHEMBL3012849

SCHEMBL3012849

O=S(=O)(c1ccc(Br)cc1)C1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.58
RAB9A P51151 7/20 0.58
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
NPC1 O15118 5/20 0.58
MAPT P10636 5/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
HPGD P15428 1/20 0.58
LMNA P02545 3/20 0.55
MAPK1 P28482 3/20 0.55
AR P10275 3/20 0.53
TP53 P04637 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 1/20 0.50
CYP2D6 P10635 1/20 0.50
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008228 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3012975 0.89 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3014611 0.89 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3012045 0.89 RAB9A (0.58) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3009419 0.89 SMN1; SMN2 (0.60) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3011753 0.89 KMT2A (0.58) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3012682 0.88 MEN1 (0.52) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3006597 0.88 LMNA (0.55) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3001245 0.88 SMN1; SMN2 (0.49) SMN1; SMN2RAB9AMEN1KMT2ANPC1
SCHEMBL3020201 0.87 AR (0.53) SMN1; SMN2RAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.